Lyell Immunopharma (LYEL) Current Assets (2020 - 2025)
Lyell Immunopharma (LYEL) has disclosed Current Assets for 6 consecutive years, with $260.9 million as the latest value for Q4 2025.
- Quarterly Current Assets fell 31.26% to $260.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $260.9 million through Dec 2025, down 31.26% year-over-year, with the annual reading at $260.9 million for FY2025, 31.26% down from the prior year.
- Current Assets hit $260.9 million in Q4 2025 for Lyell Immunopharma, down from $328.2 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $834.8 million in Q2 2021 to a low of $260.9 million in Q4 2025.
- Historically, Current Assets has averaged $532.2 million across 5 years, with a median of $586.9 million in 2023.
- Biggest five-year swings in Current Assets: rose 4.53% in 2022 and later plummeted 43.54% in 2025.
- Year by year, Current Assets stood at $626.3 million in 2021, then grew by 3.99% to $651.3 million in 2022, then decreased by 14.83% to $554.7 million in 2023, then crashed by 31.57% to $379.6 million in 2024, then tumbled by 31.26% to $260.9 million in 2025.
- Business Quant data shows Current Assets for LYEL at $260.9 million in Q4 2025, $328.2 million in Q3 2025, and $282.2 million in Q2 2025.